NEW YORK – (March 26, 2025) – Rarecells, Inc., a pioneering company in liquid biopsy, is pleased to announce the appointment of Dr. Neil Kurtz to its Board of Directors. Dr. Kurtz, a renowned healthcare entrepreneur and executive, brings over 40 years of experience in the pharmaceutical, contract research, post-acute care, and medical diagnostic sectors.
Dr. Kurtz has a distinguished career as a founder of several successful companies, including Medidata Systems and Worldwide Clinical Trials, which collectively generated over $8 billion in value forinvestors. He has served as CEO of both public and private companies and has held senior executive positions in top pharmaceutical and healthcare organizations.
“We are delighted to welcome Dr. Kurtz to our Board of Directors," said Dr. Patrizia Paterlini, CEO of Rarecells, Inc.His extensive expertise in biomedical company growth, finance, and scientific research will be invaluable as we continue to develop and commercialize our innovative technology for early detection of cancer and cancer recurrence. His addition to our Board strengthens our commitment to delivering unparalleled, non-invasive access to tumor DNA through combined CTC-DNA, ctDNA analyses. We are confident that Dr. Kurtz’s leadership will enhance our efforts to bring cutting-edge solutions to the forefront of precision oncology.”
“I am honored to join the already exceptional Board of Directors at Rarecells,” said Dr. Kurtz. “I am aligned with the company’s belief that its ISET® technology has the potential to revolutionize cancer diagnostics and personalized treatment, having a profound impact on the lives of millions of patients worldwide.”
The other members of Rarecells’ Board of Directors are Patrizia Paterlini MD, PhD, President, CEO & Founder; Neil Gunn, PhD, former head of Roche Molecular Systems and Roche Sequencing; Christian Brechot MD, PhD, Senior Associate Dean for Research in Global Affairs at the University of South Florida, Tampa; Thierry de Marignac, Former Partner at Banque Mirabaud & Cie & Leading Investor.
About Rarecells, Inc.
Rarecells, Inc. is a leading company in the development of innovative non-invasive tests for early cancer diagnosis based on the proprietary hypersensitive approaches of combined CTC-DNA, ctDNA molecular detection and AI-based Circulating Tumor Cells (CTCs) identification. Founded in 2012, the firm is headquartered in New York with offices and laboratories in New York and Paris.
For more information,
visit www.rarecells.com
Contact: media@rarecells.com